Loss

Class Action Lawsuit Filed on Behalf of Nextdoor Holdings, Inc. (KIND) Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Retrieved on: 
Thursday, February 29, 2024
Nextdoor, ISS, ARPU, Fraud, COVID-19, Loss, Mergers and acquisitions

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Nextdoor Holdings, Inc. (“Nextdoor” or the “Company”) (NYSE: KIND) f/k/a Khosla Ventures Acquisition Co. II.

Key Points: 
  • ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Nextdoor Holdings, Inc. (“Nextdoor” or the “Company”) (NYSE: KIND) f/k/a Khosla Ventures Acquisition Co. II.
  • at [email protected] , by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/nextdoor/ to learn more.
  • More information about the firm is available through its website, www.holzerlaw.com , and upon request from the firm.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024
Acquisition, Cipaglucosidase alfa, PIN, CER1, CER, Growth, Table, Loss, Amicus Therapeutics, GAAP, Therapy, Patient, Net, Diagnosis, Depreciation, Pharmaceutical industry

At the end of 2023, there were >2,400 people living with Fabry disease on Galafold following a year of increased demand.

Key Points: 
  • At the end of 2023, there were >2,400 people living with Fabry disease on Galafold following a year of increased demand.
  • Eleven posters and an oral presentation highlighting Amicus’ development programs in Fabry disease and Pompe disease presented at the 20th Annual WORLDSymposium™.
  • ET to discuss the full-year 2023 financial results and corporate updates.
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Ambarella, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Radar, Spondias dulcis, HD, Growth, Loss, Perception, CV3, GAAP, CV5, Bank

SANTA CLARA, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced fourth quarter and full year fiscal 2024 financial results for the period ended January 31, 2024.

Key Points: 
  • SANTA CLARA, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced fourth quarter and full year fiscal 2024 financial results for the period ended January 31, 2024.
  • Revenue for the fourth quarter of fiscal 2024 was $51.6 million, down 38.1% from $83.3 million in the same period in fiscal 2023.
  • Gross margin under U.S. generally accepted accounting principles (GAAP) for the fourth quarter of fiscal 2024 was 59.8%, compared with 59.6% for the same period in fiscal 2023.
  • Financial results on a non-GAAP basis for the fourth quarter and full year fiscal 2024 are as follows:
    Gross margin on a non-GAAP basis for the fourth quarter of fiscal 2024 was 62.5%, compared with 63.5% for the same period in fiscal 2023.

ALVR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, February 27, 2024
Court, Loss, Person, Complaint

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ALVR .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ALVR .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the AlloVir's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

PubMatic Announces Record Fourth Quarter and Fiscal Year Ended 2023 Financial Results; Board of Directors Expands Share Repurchase Program by $100 Million

Retrieved on: 
Monday, February 26, 2024
Engineering, Analysis, CITY, Conversation, Investment, Net, AMC, Form 10-K, Canadian Tire money, Growth, Activate, Annual report, IDS, SPO, Webcast, TiVo, AMC Networks, Privacy, Connect, ROI, Share repurchase, Disclosure, Freewheel, Advertising, GAAP, Ecosystem, Result, Conversion, Depreciation, Sandbox, Side platform, Yahoo!, Privacy Sandbox, Loss, Adjustment, CTV, Public expenditure, Interactivity, CFO, Acquisition, Collection, FOX, PMP, IQIYI, Failure, Video game

NO-HEADQUARTERS/REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • In addition to top line revenue acceleration, we continued our long track record of strong profitability, high margins, and generated record free cash flow.
  • Ended Q4 2023 with over 45% of total activity coming from Supply Path Optimization (SPO), up from 34% in Q4 2022.
  • On February 26, 2024 we announced that our Board of Directors has authorized an extension of our existing share repurchase program.
  • For the first quarter of 2024, we expect revenue to be in the range of $61 million to $63 million.

Agora, Inc. Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Monday, February 26, 2024
Cloud, Acquisition, ADS, RTE, Total, Prospectus, CEC, Research, API, Share repurchase, Marketing, Investment, Rate, Growth, Table, Loss, Government, IPO, Income tax, GAAP, COVID-19, Security (finance), Software, Bank statement, Depreciation, Video game

Agora: $15.3 million for the quarter, a decrease of 3.2% from $15.8 million in the fourth quarter of 2022.

Key Points: 
  • Agora: $15.3 million for the quarter, a decrease of 3.2% from $15.8 million in the fourth quarter of 2022.
  • Net loss for the quarter was $2.6 million, compared to net loss of $35.1 million in the fourth quarter of 2022.
  • Adjusted EBITDA for the quarter was negative $2.0 million, compared to negative $8.5 million in the fourth quarter of 2022.
  • Free cash flow for the quarter was $3.4 million, compared to negative $6.1 million in the fourth quarter of 2022.

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 26, 2024
AAAAI, Injection, KIT, Research, Dermatology, Omalizumab, Eosinophilic esophagitis, B cell, Hypersensitivity, Quality of life, Work, Prurigo nodularis, Loss, DLQI, ILT4, Data, PD-1, Contingency, Inflammation, Cell, Myelocyte, Rockefeller University, Therapy, PN, Allergy, WCI, UAS7, Patient, Dermatology Life Quality Index, CSU, Survival, Congress, Disease, G&A, Itch, SRS, American Academy, Pharmaceutical industry

HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
  • Celldex is currently planning for the initiation of a Phase 2 subcutaneous study in prurigo nodularis (PN) in early 2024.
  • The litigation settlement related loss had a ($0.26) impact on net loss per share for the twelve months ended December 31, 2023.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.

LiveView Technologies Founder and CEO Ryan Porter Discusses Small Business Support at White House

Retrieved on: 
Monday, February 26, 2024
Loss, LVT, NEC, Education, Transport, Government, Safety, Private sector, Small Business Administration, SBA

AMERICAN FORK, Utah, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LiveView Technologies (LVT) Founder and CEO Ryan Porter joined a select group of business leaders for a White House roundtable this month.

Key Points: 
  • AMERICAN FORK, Utah, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LiveView Technologies (LVT) Founder and CEO Ryan Porter joined a select group of business leaders for a White House roundtable this month.
  • The discussion, hosted by the White House National Economic Council (NEC) and the Small Business Administration (SBA), explored how new reforms will support investment in underserved and capital-constrained markets.
  • “Startups are wells of innovation, providing new-age solutions that can significantly change the nation’s approach to critical technology and manufacturing,” said Porter.
  • Since then, LVT has strengthened security for hundreds of companies spanning construction, education, government, retail, transportation, and other key sectors.

Maplebear Inc. d/b/a Instacart Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2024 to Discuss Your Rights – CART

Retrieved on: 
Monday, February 26, 2024
Court, NEXT, Person, Telephone, COST, Loss, CLASS, LLP

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maplebear Inc. d/b/a Instacart ("Maplebear" or the "Company") (NASDAQ: CART) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maplebear Inc. d/b/a Instacart ("Maplebear" or the "Company") (NASDAQ: CART) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maplebear investors who were adversely affected by alleged securities fraud.
  • Follow the link below to get more information and be contacted by a member of our team:
    CART investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

AlloVir, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ALVR

Retrieved on: 
Monday, February 26, 2024
The Company, Court, NEXT, Telephone, COST, Loss, CLASS, LLP, Cryptocurrency

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    ALVR investors may also contact Joseph E. Levi, Esq.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.